Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

118-LB: Glucose Variability throughout the Menstrual Cycle on Closed-Loop Control in Type 1 DM

View through CrossRef
Many women with type 1 DM report change in glucose (GLU) control and insulin (INS) dosing throughout the menstrual cycle (MC). No trials have reported the effect of closed loop control (CLC) on INS delivery across the MC. Women enrolled in Phase 1 of the IDCL hybrid CLC trial logged MCs to estimate late luteal and early follicular dates. Data from 64 MC across 27 women (13 CLC), 7 using hormonal contraception, aged 28±11 years, weight 67 kg (IQR: 61-80) was analyzed for diurnal GLU control and CLC INS delivery. MC phase did not impact trends toward increased time in range with CLC. There were no differences in GLU and INS variables. While median CLC INS delivery did not change across the MC, there was intrasubject variability across the MC. CLC has the potential to elucidate individual dosing variability and may mitigate reported change in GLU control across the MC. Disclosure C.J. Levy: Advisory Panel; Self; Novo Nordisk A/S, Sanofi. Employee; Spouse/Partner; Allergan. G. OMalley: None. S.A. Brown: Research Support; Self; Ascensia Diabetes Care, Dexcom, Inc., Roche Diabetes Care, Tandem Diabetes Care. D. Raghinaru: None. Y.C. Kudva: Advisory Panel; Self; Novo Nordisk Inc. Other Relationship; Self; Dexcom, Inc., Roche Diabetes Care, Tandem Diabetes Care. E. Dassau: Consultant; Self; Eli Lilly and Company, Insulet Corporation. Research Support; Self; Dexcom, Inc., DreaMed Diabetes, Ltd., Insulet Corporation, Roche Diabetes Care, Tandem Diabetes Care, Xeris Pharmaceuticals, Inc. Speaker’s Bureau; Self; Roche Diabetes Care. Other Relationship; Self; ModAGC. B. Kovatchev: Advisory Panel; Self; Sanofi. Board Member; Self; TypeZero Technologies, Inc. Consultant; Self; Sanofi, Tandem Diabetes Care. Research Support; Self; Dexcom, Inc., Roche Diabetes Care, Tandem Diabetes Care. Speaker’s Bureau; Self; Dexcom, Inc. Stock/Shareholder; Self; TypeZero Technologies, Inc. Other Relationship; Self; Johnson & Johnson, Sanofi. S. Anderson: Research Support; Self; Medtronic MiniMed, Inc. Funding National Institutes of Health
Title: 118-LB: Glucose Variability throughout the Menstrual Cycle on Closed-Loop Control in Type 1 DM
Description:
Many women with type 1 DM report change in glucose (GLU) control and insulin (INS) dosing throughout the menstrual cycle (MC).
No trials have reported the effect of closed loop control (CLC) on INS delivery across the MC.
Women enrolled in Phase 1 of the IDCL hybrid CLC trial logged MCs to estimate late luteal and early follicular dates.
Data from 64 MC across 27 women (13 CLC), 7 using hormonal contraception, aged 28±11 years, weight 67 kg (IQR: 61-80) was analyzed for diurnal GLU control and CLC INS delivery.
MC phase did not impact trends toward increased time in range with CLC.
There were no differences in GLU and INS variables.
While median CLC INS delivery did not change across the MC, there was intrasubject variability across the MC.
CLC has the potential to elucidate individual dosing variability and may mitigate reported change in GLU control across the MC.
Disclosure C.
J.
Levy: Advisory Panel; Self; Novo Nordisk A/S, Sanofi.
Employee; Spouse/Partner; Allergan.
G.
OMalley: None.
S.
A.
Brown: Research Support; Self; Ascensia Diabetes Care, Dexcom, Inc.
, Roche Diabetes Care, Tandem Diabetes Care.
D.
Raghinaru: None.
Y.
C.
Kudva: Advisory Panel; Self; Novo Nordisk Inc.
Other Relationship; Self; Dexcom, Inc.
, Roche Diabetes Care, Tandem Diabetes Care.
E.
Dassau: Consultant; Self; Eli Lilly and Company, Insulet Corporation.
Research Support; Self; Dexcom, Inc.
, DreaMed Diabetes, Ltd.
, Insulet Corporation, Roche Diabetes Care, Tandem Diabetes Care, Xeris Pharmaceuticals, Inc.
Speaker’s Bureau; Self; Roche Diabetes Care.
Other Relationship; Self; ModAGC.
B.
Kovatchev: Advisory Panel; Self; Sanofi.
Board Member; Self; TypeZero Technologies, Inc.
Consultant; Self; Sanofi, Tandem Diabetes Care.
Research Support; Self; Dexcom, Inc.
, Roche Diabetes Care, Tandem Diabetes Care.
Speaker’s Bureau; Self; Dexcom, Inc.
Stock/Shareholder; Self; TypeZero Technologies, Inc.
Other Relationship; Self; Johnson & Johnson, Sanofi.
S.
Anderson: Research Support; Self; Medtronic MiniMed, Inc.
Funding National Institutes of Health.

Related Results

Menstrual Health Literacy Among Young Female Adults in Northern Mindanao: A Descriptive Cross-sectional Study
Menstrual Health Literacy Among Young Female Adults in Northern Mindanao: A Descriptive Cross-sectional Study
Background and Purpose: Menstrual health literacy (MHL) refers to an individual’s ability to access, understand and apply accurate information about menstruation, including biologi...
HUBUNGAN KONSUMSI BUAH DAN SAYUR SERTA KOPI READY TO DRINK TERHADAP KEJADIAN GANGGUAN SIKLUS MENSTRUASI REMAJA PUTRI
HUBUNGAN KONSUMSI BUAH DAN SAYUR SERTA KOPI READY TO DRINK TERHADAP KEJADIAN GANGGUAN SIKLUS MENSTRUASI REMAJA PUTRI
ABSTRACTBackground: As many as 75% of adolescents women aged 12-24 years old experience menstrual cycle disorders. Menstrual cycle disorders are disorders experienced by a woman du...
Closed-loop identification for aircraft flutter model parameters
Closed-loop identification for aircraft flutter model parameters
Purpose The purpose of this paper is to extend the authors’ previous contributions on aircraft flutter model parameters identification. Because closed-loop condition is more widely...
Menstrual cycle changes among female athletes post a traumatic brain injury: A systematic review
Menstrual cycle changes among female athletes post a traumatic brain injury: A systematic review
Introduction: Traumatic brain injury (TBI) commonly affects athletes and can lead to menstrual cycle changes in female athletes. This review highlights the existing literature on m...
Bioinformatics Analysis of Gefitinib or Rapamycin on Inhibiting the Survival of Hela in the Low Glucose and High Lactic Acid Environment
Bioinformatics Analysis of Gefitinib or Rapamycin on Inhibiting the Survival of Hela in the Low Glucose and High Lactic Acid Environment
Objective: To explore on the antitumor effect of gefitinib and rapamycin and possible mechanism in normal glucose and high lactic acid microenvironment. Methods: Hela cells are cul...
The Relationship Between Stress Level and Menstrual Cycle in Final Year Students
The Relationship Between Stress Level and Menstrual Cycle in Final Year Students
Introduction: According to the World Health Organisation (WHO), 38.45% of adolescent problems are related to menstrual disorders. Menstrual disorders are abnormalities that occur i...

Back to Top